Precigen, Inc. (PGEN) Income Statement Analysis

See more : NEXT Biometrics Group ASA (NEXT.OL) Income Statement Analysis – Financial Results

Complete financial analysis of Precigen, Inc. (PGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Precigen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

BowX Acquisition Corp. (BOWXU) Income Statement Analysis – Financial Results
LMF Acquisition Opportunities, Inc. (LMAOU) Income Statement Analysis – Financial Results
GRIID Infrastructure Inc. Common Stock (GRDI) Income Statement Analysis – Financial Results
Nur Ink Innovations Ltd (NURI.TA) Income Statement Analysis – Financial Results
Remsense Technologies Limited (REM.AX) Income Statement Analysis – Financial Results

Precigen, Inc. (PGEN)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.precigen.com

About Precigen, Inc.

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	6.23M	26.91M	103.87M	103.18M	90.72M	160.57M	230.98M	190.93M	173.61M	71.93M	23.76M	13.93M	8.01M
Cost of Revenue	6.12M	6.34M	58.39M	55.51M	61.40M	63.29M	62.79M	61.64M	63.93M	19.26M	48.17M	64.03M	0.00
Gross Profit	106.00K	20.57M	45.49M	47.67M	29.32M	97.29M	168.19M	129.29M	109.68M	52.67M	-24.41M	-50.11M	8.01M
Gross Profit Ratio	1.70%	76.44%	43.79%	46.20%	32.32%	60.59%	72.82%	67.72%	63.18%	73.22%	-102.71%	-359.85%	100.00%
Research & Development	48.61M	47.17M	50.14M	41.64M	101.88M	404.59M	143.21M	112.14M	147.48M	58.98M	48.17M	64.19M	70.23M
General & Administrative	0.00	0.00	0.00	0.00	0.00	137.81M	146.10M	142.32M	109.06M	63.65M	33.62M	24.90M	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	40.42M	48.01M	74.12M	91.70M	100.84M	137.81M	146.10M	142.32M	109.06M	63.65M	33.62M	24.90M	18.30M
Other Expenses	0.00	1.54M	-330.00K	-165.00K	3.45M	630.00K	1.01M	1.70M	1.31M	-168.00K	-162.00K	-101.00K	-1.00K
Operating Expenses	84.18M	95.18M	124.26M	133.35M	202.72M	542.39M	289.31M	254.45M	256.54M	122.63M	81.78M	89.08M	90.44M
Cost & Expenses	95.15M	101.52M	182.65M	188.86M	264.12M	605.68M	352.10M	316.09M	320.47M	141.89M	81.78M	89.08M	90.44M
Interest Income	3.24M	133.00K	1.62M	2.45M	3.87M	19.08M	19.49M	10.19M	1.88M	806.00K	166.00K	5.00K	0.00
Interest Expense	468.00K	6.77M	18.89M	18.40M	17.67M	8.53M	611.00K	861.00K	1.24M	666.00K	141.00K	57.00K	183.00K
Depreciation & Amortization	6.67M	7.19M	8.14M	15.04M	16.14M	24.11M	31.15M	24.57M	17.74M	10.42M	7.21M	7.98M	4.34M
EBITDA	-89.23M	-66.00M	-84.07M	-70.41M	-137.46M	-349.06M	-97.94M	-168.72M	-67.99M	-74.64M	-33.56M	-73.83M	-80.76M
EBITDA Ratio	-1,433.35%	-267.84%	-74.60%	-81.93%	-185.73%	-272.15%	-49.75%	-70.39%	-87.91%	-103.69%	-247.44%	-485.08%	-974.54%
Operating Income	-88.92M	-74.61M	-78.78M	-85.68M	-173.40M	-505.61M	-137.89M	-125.17M	-146.86M	-69.96M	-58.02M	-75.16M	-82.43M
Operating Income Ratio	-1,428.48%	-277.25%	-75.84%	-83.04%	-191.14%	-314.88%	-59.70%	-65.56%	-84.60%	-97.26%	-244.20%	-539.73%	-1,028.67%
Total Other Income/Expenses	-7.44M	-5.36M	-19.56M	-18.35M	-35.29M	-26.25M	17.80M	-68.99M	59.89M	-15.76M	17.12M	-6.72M	-2.85M
Income Before Tax	-96.36M	-79.97M	-96.93M	-103.86M	-208.69M	-536.23M	-129.70M	-194.15M	-86.98M	-85.72M	-40.91M	-81.87M	-85.28M
Income Before Tax Ratio	-1,547.98%	-297.17%	-93.31%	-100.66%	-230.03%	-333.95%	-56.15%	-101.69%	-50.10%	-119.17%	-172.17%	-587.96%	-1,064.27%
Income Tax Expense	-458.00K	-189.00K	-160.00K	-82.00K	-930.00K	-21.53M	-2.88M	-3.88M	1.02M	-103.00K	-9.76M	-318.00K	182.00K
Net Income	-95.90M	-79.78M	-96.77M	-103.77M	-207.76M	-509.34M	-117.02M	-186.61M	-84.49M	-81.82M	-38.98M	-81.87M	-85.28M
Net Income Ratio	-1,540.63%	-296.47%	-93.16%	-100.58%	-229.00%	-317.20%	-50.66%	-97.74%	-48.67%	-113.75%	-164.06%	-587.96%	-1,064.27%
EPS	-0.39	-0.40	-0.49	-0.62	-1.35	-3.93	-0.98	-1.58	-0.76	-0.83	-0.95	-14.80	-15.05
EPS Diluted	-0.39	-0.40	-0.49	-0.62	-1.35	-3.93	-0.98	-1.58	-0.76	-0.83	-0.95	-14.80	-15.05
Weighted Avg Shares Out	244.54M	200.36M	197.76M	167.07M	154.14M	129.52M	120.00M	117.98M	111.07M	99.17M	40.95M	5.53M	5.66M
Weighted Avg Shares Out (Dil)	244.54M	200.36M	197.76M	167.07M	154.14M	129.52M	120.00M	117.98M	111.07M	99.17M	40.95M	5.53M	5.66M

Precigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates

November 14, 2024zacks.com

Precigen, Inc. (PGEN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.08 per share a year ago.

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

November 14, 2024prnewswire.com

– Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012 † in RRP under accelerated approval pathway – – Commercial and manufacturing readiness...

Precigen to Participate in the Stifel 2024 Healthcare Conference

November 12, 2024prnewswire.com

GERMANTOWN, Md. , Nov. 12, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will...

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

September 16, 2024prnewswire.com

GERMANTOWN, Md. , Sept. 16, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO...

3 Penny Stocks To Buy With Just $50

September 15, 2024247wallst.com

Penny stocks are an interesting category. While they have the potential to produce significant long-run gains, you should never bet money on these stocks that you can't afford to lose.